HER-2+ cancer immunotherapy that stimulates a polyclonal antibody response to HER-2

Imugene’s lead product is a Phase 2 ready HER-2+ gastric cancer immunotherapy for the treatment of cancers expressing the HER-2 receptor. The Company also has a research programme focused on antigen mimotopes for use in cancer vaccines.

Imugene-pipeline-diagram.png

 

 
 
 

© Imugene 2017. All rights reserved. ABN 99 009 179 551